TrialCancer medicine2023

First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial.

Hye Ryun Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.